Abcam, ab281571, Anti-TDO2/TDO antibody [EPR23745-311] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal TDO2/TDO antibody. Carrier free. Suitable for ICC/IF, IP, WB and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23745-311,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:ICC/IF, IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab281571 is the carrier-free version of
ab259359
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TDO2 also known as tryptophan 23-dioxygenase is an enzyme that catalyzes the initial and rate-limiting step in the kynurenine pathway degrading tryptophan to N-formylkynurenine. This reaction is important for regulating systemic tryptophan levels. TDO2 is a heme-containing enzyme with a molecular mass of approximately 53 kDa. It is highly expressed in the liver unlike its counterpart indoleamine 23-dioxygenase (IDO) which has wider tissue distribution. Liver-specific expression suggests its role in orchestrating whole-body tryptophan metabolism.
Biological function summary
TDO2 plays a significant role in maintaining immune tolerance and modulating neurotransmitter levels. While not part of a larger complex it interacts with several other proteins to mediate its effects. By controlling tryptophan availability TDO2 impacts the production of serotonin and downstream kynurenine metabolites affecting neural and immune functions. Its activity influences both central nervous system processes and peripheral immune responses implying a broad impact on various physiological systems.
Pathways
TDO2's function integrates into the kynurenine and serotonin pathways. In the kynurenine pathway TDO2's enzymatic activity leads to the generation of metabolites such as kynurenine and quinolinic acid which have immunoregulatory and excitotoxic properties. The serotonin pathway also indirectly involves TDO2 as it limits tryptophan's availability for serotonin synthesis. TDO2 interacts with IDO in controlling the balance of tryptophan metabolites providing a link between immune signaling and central nervous system regulation.
TDO2 has been implicated in cancer and neurodegenerative diseases. Overexpression of TDO2 is observed in various cancers where it helps create an immune-suppressive environment that aids tumor survival. The enzyme’s upregulation affects tumor microenvironment dynamics often acting in concert with IDO which further mediates immune escape. TDO2's activity may also contribute to neurodegenerative disorders through its impact on kynurenine pathway metabolites which can be neurotoxic. The interplay between TDO2 and IDO suggests that targeting this enzymatic pathway could offer therapeutic avenues in both oncological and neuropsychiatric conditions.